Parkinson's disease (PD) is a common, progressive neurodegenerative disorder
characterized by substantia nigra dopamine cell death and a varied clinical picture that …

Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer's disease and it is characterized by the progressive loss of dopaminergic neurons …

Parkinson's disease (PD) manifests with a typical movement disorder, due to the loss of
dopaminergic neurons of the substantia nigra. There are no disease-modifying treatments …

Current findings suggest that multipotent stem cells may be suitable for cell replacement
therapies in the treatment of neurodegenerative disorders. Embryonic stem (ES) cells are …

Parkinson's disease (PD) is the most common movement disorder. The neuropathology is
characterized by the loss of dopamine neurons in the substantia nigra pars compacta …

Parkinson's disease (PD) is one of the most frequent neurodegenerative diseases and
represents a major therapeutic challenge because of the so far missing therapeutic means …

Currently the mainstay of Parkinson's disease (PD) therapy is the pharmacological
replacement of the loss of the dopaminergic nigrostriatal pathway using drugs such as …

The quest for new and improved therapies for Parkinson's disease (PD) remains of
paramount importance, despite previous trial failures. There is a current debate regarding …

Cell replacement therapies in Parkinson's disease (PD) aim to provide long-lasting relief of
patients' symptoms. Previous clinical trials using transplantation of human fetal ventral …

Although the concept of cell-based therapy for Parkinson's disease has been around for
more than three decades with proof-of-concept studies in man having been achieved, it still …